Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Imatinib
Gleevec · 1 trial · 1 indication
TTP is the amount of time from date of registration to date of first documentation of progression or symptomatic deterioration. For progression, one or more of the following must occur: (1) 20% increase in the sum of longest diameters of target measurable lesions over smallest sum observed (over baseline if no decrease during therapy) using the same techniques as baseline. (2) Increase in PSA by at least 25% from baseline in patients whose PSA did not decrease, and of 50% from nadir in patients whose PSA decreased with a confirmation 3 weeks later. (3) Unequivocal progression of non-measurable disease in the opinion of the treating physician (an explanation must be provided). (4) Appearance of any new lesion/site. (5) Death due to disease without prior documentation of progression and without symptomatic deterioration, which is defined as global deterioration of health status requiring discontinuation of treatment without objective evidence of progression.
| Arm | Type | Description |
|---|---|---|
| Hormone Refractory Prostate Cancer | EXPERIMENTAL | Gleevec + Docetaxel: Daily Oral Gleevec in Combination with Every-Three-Week Intravenous Docetaxel |
| Name | Type | Description |
|---|---|---|
| Gleevec | DRUG | Imatinib-400mg po qd for 10 days to commence on day 3. On day 0, Docetaxel 60mg/m\^2 administered IV |
| Docetaxel | DRUG | 60 mg/m\^2 administered IV on day 0 |
Inclusion Criteria: 1. Must have a histologic diagnosis of adenocarcinoma of the prostate Stage D2 that is unresponsive or refractory to hormone therapy. Must have metastatic prostate cancer with a rising PSA, and deemed to be hormone refractory. 2. All subjects must have pre-study PSA within 28 da...
Top 20 of 53 competitors
Gleevec is being studied for use in prostate cancer and lung cancer. It is an investigational small molecule oncology drug being evaluated in Phase 2 clinical trials for these indications. Gleevec is also known as imatinib.
Gleevec is a kinase inhibitor, belonging to the -tinib class of drugs. It works by targeting kinases, which are enzymes involved in cell signaling and growth. This mechanism is relevant to its evaluation in cancer treatment.
Gleevec is developed by Novartis AG, a company traded on the stock exchange under the ticker symbol NVS. Novartis is conducting clinical trials to evaluate Gleevec for prostate cancer and lung cancer.
Gleevec is in Phase 2 clinical development for prostate cancer and lung cancer. It is an investigational drug, meaning it has not been approved by regulatory authorities for these uses and is still undergoing clinical evaluation.
Gleevec has been studied in two completed Phase 2 trials. NCT00222144 evaluated Gleevec with Taxotere in recurrent non-small cell lung cancer with 23 participants. NCT00251225 studied imatinib with docetaxel in prostate cancer with 49 male participants. Both trials were conducted in the United States.
Yes, Gleevec is the same as imatinib. Imatinib is the generic name for the drug, while Gleevec is a brand name. Clinical trials may refer to the drug by either name, such as in NCT00251225 which uses imatinib in its title.